PKCiota-IN-49 CAS No.:2230055-52-2

Introduction:

We are pleased to introduce our high-quality product PKCiota-IN-49 CAS No.:2230055-52-2. As a leading manufacturer in China, we are committed to providing superior products and services to our customers worldwide.

Our PKCiota-IN-49 is a cutting-edge chemical compound designed for a wide range of applications. It is a potent inhibitor of PKCiota, and it has shown great promise in various preclinical studies. In this product introduction, we will provide a detailed overview of the benefits and applications of PKCiota-IN-49, as well as its key features and characteristics.

What is PKCiota-IN-49?

PKCiota-IN-49 is a small molecule inhibitor of PKCiota, a protein kinase that is implicated in several cancer pathways. PKCiota-IN-49 targets the ATP-binding site of PKCiota and reduces its activity. This can lead to the inhibition of cancer cell growth and survival, which makes it a promising candidate for cancer therapy.

Features and Benefits:

PKCiota-IN-49 has several features that make it an excellent option for researchers and pharmaceutical companies. One of the key advantages of this product is its selectivity. It targets PKCiota specifically, which means that it has minimal off-target effects. This is important because it reduces the risk of toxicity and improves the efficacy of the drug.

Another benefit of PKCiota-IN-49 is its activity. It has been shown to be a potent inhibitor of PKCiota, with an IC50 value of 2.9 nM. This high activity makes it an attractive option for researchers looking to study PKCiota signaling pathways or develop new cancer drugs.

PKCiota-IN-49 also has excellent pharmacokinetic properties. It is stable in plasma and has good oral bioavailability, which means that it can be administered via multiple routes, including oral and intravenous. This makes it a versatile tool for researchers and clinicians.

Applications:

PKCiota-IN-49 has several potential applications in cancer therapy and research. Some of these include:

1. Targeted cancer therapy: As a potent inhibitor of PKCiota, PKCiota-IN-49 has great potential as a targeted cancer therapy. It can potentially inhibit the growth and proliferation of cancer cells without affecting normal cells, which reduces the risk of side effects and toxicity.

2. Cancer biomarker: PKCiota is overexpressed in several types of cancer, including breast, lung, and ovarian cancer. PKCiota-IN-49 can be used as a biomarker to identify cancer patients who are likely to benefit from PKCiota targeting therapies.

3. Research tool: PKCiota-IN-49 can be used as a research tool to study PKCiota signaling pathways and mechanisms of action. It can also be used to develop new cancer drugs that target PKCiota.

Conclusion:

In summary, our PKCiota-IN-49 is an innovative and versatile product with great potential in cancer therapy and research. With its high activity, selectivity, and pharmacokinetic properties, it is an attractive option for pharmaceutical companies and researchers. We are committed to providing superior products and services to our customers worldwide, and we are confident that PKCiota-IN-49 will meet your needs and exceed your expectations. For more information or to place an order, please contact us today.

Chemical Structure : PKCiota-IN-49

CAS No.: 2230055-52-2

 

PKCiota-IN-49

Catalog No.: URK-V2349 Only Used For Lab.

PKCiota-IN-49 is a potent and selective inhibitor of Protein Kinase C iota (PKC-ι) with IC50 of 2.8 nM, >20-fold selectivity over PKC-α (IC50=71 nM) and PKC-β (IC50=350 nM).

Biological Activity

PKCiota-IN-49 is a potent and selective inhibitor of Protein Kinase C iota (PKC-ι) with IC50 of 2.8 nM, >20-fold selectivity over PKC-α (IC50=71 nM) and PKC-β (IC50=350 nM).
PKCiota-IN-49 inhibits PKC-ι on the phosphorylation of substrate ECT2 in HCCLM3 cells with IC50 of 3.0 uM.

Physicochemical Properties

References

1. Kwiatkowski J, et al. J Med Chem. 2018 May 4. doi: 10.1021/acs.jmedchem.8b00060.

URK-V2349_COA

URK-V2349_SDS

URK-V2349_TDS

 

Note: All products of Ureiko are only used for scientific research or drug certificate declaration, and we do not provide products and services for any personal use!

Why choose us?

• Our products are backed by our commitment to quality, ensuring that every order is fulfilled with the utmost care and attention to detail.
• We insist on facing the market, adapting to the market, participating in market competition and learning to operate.
• With our extensive experience and expertise, we continuously strive to exceed our customers' expectations.
• We are driven by customer needs, have a sensitive market response capability, and implement a focused business model.
• We are committed to providing exceptional customer service and support.
• We possess a sense of the big picture that collective value is higher than individual value and individual interests are subordinated to collective interests.
• Our expert team is always looking for new ways to enhance our products and services to better meet our customers' needs.
• Quality is the life of an enterprise, the display of the overall quality of an enterprise, and the embodiment of the comprehensive strength of an enterprise.
• Our products are engineered to deliver consistent results, time and time again.
• We thinks what buyers think, the urgency of urgency to act during the interests of a purchaser position of theory, allowing for much better high-quality, reduced processing costs, charges are more reasonable, won the new and outdated consumers the support and affirmation for PKCiota-IN-49 CAS No.:2230055-52-2.

Hot Tags: pkciota-in-49 cas no.:2230055-52-2, China pkciota-in-49 cas no.:2230055-52-2, epigenetic library for epigenetic enhancement, inhibitors for orthopedic research, epigenetic library for epigenetic analysis of epigenetic biomarker validation, inhibitors for drug resistance, epigenetic library for epigenetic induction, epigenetic library for epigenetic syndrome